ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 344

Real World Clinical Trial Comparing the Patient Reported Outcomes Measurement Information System Short Forms and Profiles to CDAI Disease Classification in Rheumatoid Arthritis Patients

Jeffrey R. Curtis1, Sergio Schwartzman2, Shelly Kafka3, Dennis Parenti3, Shawn Black3, Stephen Xu4, Wayne Langholff4 and Clifton O. Bingham III5, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2Weill Cornell Medical College, New York, NY, 3Janssen Scientific Affairs, LLC, Horsham, PA, 4Janssen Research & Development, LLC, Spring House, PA, 5Rheumatology, Johns Hopkins University, Baltimore, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Assessment, Biologics, patient outcomes and rheumatoid arthritis (RA), PROMIS

Session Information

Date: Sunday, November 5, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient (Pt) reported outcomes (PROs) play a role in overall disease evaluation, therapeutic response assessment and care of rheumatoid arthritis (RA) patients (Pts). The Pt Reported Outcomes Measurement Information System (PROMIS [P]) questionnaires developed by the NIH have been used in clinical practice and observational studies in RA (Bartlett 2015). AWARE (Comparative and Pragmatic Study of Golimumab Intravenous [IV] Versus Infliximab in RA) is a large, pragmatic multi-center United States-based, real-world evidence study of golimumab IV (GLM) vs. infliximab (IFX) in RA and will assess infusion reactions, disease activity, and multiple PROs as outcomes.

Methods: AWARE is a prospective, noninterventional, ongoing study in which 1200 adult Pts will be enrolled on initiation of treatment with GLM or IFX. Objectives include PRO assessments of Pt response to treatment using the PROMIS-29 Profile v2.0 (P29v2), P Pain Interference Short Form-6b (PISF) and P Fatigue Short Form-7a (FSF), 36-Item Short Form Health Survey (SF-36v2) and Clinical Disease Activity Index (CDAI). We report here an interim analysis of 747 pts’ baseline PROMIS questionnaire and CDAI scores, and their inter-relationships. PROMIS questionnaire results are normalized to the US population and reported as a “T-score” (mean of 50 and standard deviation (SD) of 10) with higher scores indicating more of the trait being measured. PROMIS T-scores were compared between HDA with MDA, LDA and remission, respectively. Data shown are mean ± SD. Statistical testing compared T-scores across CDAI categories using ANOVA for this IA of baseline data (before drug administration). Data from GLM and IFX pts are combined.

Results: Overall baseline CDAI score was 32.5 ± 15.4, with 71.7% of pts in high DA (HDA), 22.5% in moderate disease activity (MDA), 5.2% in low disease activity (LDA) and 0.7% in remission. All P29v2 domains, PISF and FSF scores were significantly worse in pts with CDAI>22 vs. CDAI≤22 (p < 0.05), as was true for the 8 SF-36 domains (data not shown). PROMIS T-scores (P29v2 domains, PISF and FSF) were compared to the 4 CDAI disease activity categories. As shown below, PROMIS T-scores correlated with CDAI disease category, with HDA Pt T-scores significantly (*, p<0.05) different from those of MDA, LDA and Remission pts (except between HDA and remission for Anxiety, Depression and Sleep Disturbance domains).

 

Mean ± Standard Deviation of PROMIS T-Score of All Patients in Interim Analysis Dataset and a Comparison of T-Scores of PROMIS-29 Domains, Fatigue Short Form and Pain Interference Short Form to CDAI Disease Activity Category

All Patients

(n=672-682)

Remission

CDAI≤2.8

(n=5)

LDA

2.8<CDAI≤10

(n=38)

MDA

10<CDAI≤22

(n=165)

HDA

CDAI>22 (n=526)

P29-Physical Function

37.9 ± 6.6

47.5 ± 5.7

45.0 ± 7.6

40.0 ± 6.7

36.6 ± 5.9*

P29-Anxiety

53.8 ± 10.4

45.2 ± 6.7#

47.7 ± 8.6

51.3 ± 10.0

55.2 ± 10.3*

P29-Depression

52.5 ± 10.3

42.6 ± 3.6#

45.9 ± 6.5

49.4 ± 9.8

54.0 ± 10.3*

P29-Fatigue

58.8 ± 9.9

42.3 ± 5.4

 49.7 ± 9.7

55.6 ± 9.2

60.8 ± 9.4*

P29-Sleep Disturbance

55.5 ± 8.7

48.2 ± 13.6#

51.5 ± 7.9

53.2 ± 8.4

56.7 ± 8.6*

P-29 Ability to participate in Social Roles and Activities

43.2 ± 8.6

57.3 ± 7.6

50.8 ± 8.5

45.9± 8.5

41.6 ± 8.0*

P29-Pain Interference

63.5 ± 7.7

46.9 ± 7.2

53.9 ± 8.4

60.1 ± 7.7

65.4 ± 6.5*

Fatigue Short Form 7a

59.3 ± 8.5

46.7± 8.8

51.6 ± 9.0

56.2 ± 7.5

61.0 ± 8.1*

Pain Interference Short Form 6b

62.5 ± 7.6

45.9 ± 7.5

53.9 ± 9.3

59.3 ± 5.6

64.3 ± 6.4*

P29 Pain Intensity

(scored 0-10 scale)

6.0 ± 2.2

1.6 ± 2.6

3.5 ± 2.3

5.1 ± 2.2

6.6 ± 1.9*

T-scores > 50 indicate worsening of the domain relative to the general population, except “Physical Function” and “Ability to participate in Social Roles and Activities”, where T-scores < 50 indicate worsening of these domains relative to the general population. * = p<0.05 vs respective scores in MDA, LDA and remission DA categories. # = not statistically different from HDA

Conclusion: Our interim findings demonstrate the feasibility of using PROMIS short forms and profiles to evaluate RA pts in clinical trials. These results confirm the domain validity of PROMIS measures according to CDAI disease category. PROMIS measures show the range of impact across multiple domains of physical, emotional, and social health experienced by RA pts. With a fully enrolled AWARE trial, evaluation of PROs, their responsiveness over time, and comparison with SF36 will provide important additional validation for their use in clinical trials.


Disclosure: J. R. Curtis, AbbVie, Roche/Genentech, BMS, UCB, Myraid, Lilly, Amgen, Janssen, Pfizer, Corrona, 5,Amgen, Pfizer, Crescendo Bio, Corrona, 9; S. Schwartzman, AbbVie, Antares, Genentech, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, UCB, 5,AbbVie, Janssen, Genentech, Pfizer, UCB, Crescendo, Novartis, 8,Crescendo Biosciences, Discus Analytics, National Psoriasis Foundation, 6; S. Kafka, Janssen, 3,Johnson & Johnson, LLC, 1; D. Parenti, Janssen, 3,Johnson & Johnson, LLC, 1; S. Black, Janssen, 3,Johnson & Johnson, LLC, 1; S. Xu, Janssen, 3,Johnson & Johnson, LLC, 1; W. Langholff, Janssen, 3,Johnson & Johnson, LLC, 1; C. O. Bingham III, Janssen, 2,Janssen, 5.

To cite this abstract in AMA style:

Curtis JR, Schwartzman S, Kafka S, Parenti D, Black S, Xu S, Langholff W, Bingham III CO. Real World Clinical Trial Comparing the Patient Reported Outcomes Measurement Information System Short Forms and Profiles to CDAI Disease Classification in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/real-world-clinical-trial-comparing-the-patient-reported-outcomes-measurement-information-system-short-forms-and-profiles-to-cdai-disease-classification-in-rheumatoid-arthritis-patients/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-clinical-trial-comparing-the-patient-reported-outcomes-measurement-information-system-short-forms-and-profiles-to-cdai-disease-classification-in-rheumatoid-arthritis-patients/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology